The ICD wins, again -- compared with placebo, ICD therapy reduced all-cause mortality by a highly significant 23% in NYHA class II/III patients with ischemic or nonischemic dilated cardiomyopathy.

In trial, which included stricter inclusion/exclusion criteria compared with other trials, CRT improved peak VO2, NYHA class, quality of life, and exercise duration from baseline to 6 months.

A total of 267 patients were assigned to the valve-replacement group and 133 to the control group. At 1 year, the win ratio favoring valve replacement was 2.02 (95% confidence interval [CI], 1.56 ...

Bristol Myers Squibb today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos for the treatment of adult patients with symptomatic New York Heart Association class II-III non-obstructive ...

Treatment with 100 mg of EDG-7500 over four weeks demonstrated improvements on the NYHA functional class score (classifies stages of heart failure).

A total of 36 patients received nex-z and completed at least 12 months of follow-up. Of these patients, 50% were in NYHA class III and 31% had variant ATTR-CM.

However, significantly more patients had NYHA class I symptoms at 12 months when treated with the sodium-glucose cotransporter 2 (SGLT2) inhibitor instead of standard care. During a panel discussion, ...